O'Ryan.Health Launches Groundbreaking Parent-Led Pediatric Studies Utilizing YourBio Health's TAP Capillary Blood Sampling Devices
Comunicato Precedente
Comunicato Successivo
The institutional review board approved study involves healthy children and children with a JDM diagnosis. Capillary blood is drawn on a predetermined schedule using virtually painless TAP Micro devices. Guided by animated Superhero Scientists and comic book "mission reports" of their results, children take an active role in their healthcare journey and learn about their immune health.
"We are thrilled to partner with O'Ryan.Health in pioneering at-home, decentralized studies for children with JMD and healthy children alike," said Paul Owen, President and CEO, YourBio Health. "Through O'Ryan.Health's approach with TAP devices, more families and children can access and join groundbreaking research."
About YourBio Health
YourBio Health is a Flagship Pioneering portfolio company that invented 'Touch-Activated Phlebotomy' (TAP) for virtually painless capillary blood collection. Backed by the latest science and certified central laboratories, YourBio Health seeks to revolutionize and humanize the blood collection process serving clinical trials, diagnostic and wellness applications.
About O'Ryan.Health
O'Ryan.Health is introducing a pioneering initiative aimed at transforming pediatric autoimmune research and becoming the trusted brand in at-home pediatric blood sampling. O'Ryan.Health envisions a future where pediatric autoimmune diseases are not just managed but potentially cured and aims to create lasting value in the pediatric at-home blood testing market.
For more information or to enroll in O'Ryan.Health's study please visit: O'Ryan.Health.
Web: https://oryan.health/
Instagram: ORyan_Therapeutics
Logo - https://mma.prnewswire.com/media/2461303/YBH_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/oryanhealth-launches-groundbreaking-parent-led-pediatric-studies-utilizing-yourbio-healths-tap-capillary-blood-sampling-devices-302210522.html
Ufficio Stampa
PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom




